Adjuvant Durvalumab Beneficial in Esophageal/GEJ Cancer?

Fruquintinib plus chemotherapy and a PD-1 inhibitor elicited an ORR of 80.0% with all partial responses in patients with treatment-naïve gastric/GEJ cancer.

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.

The addition of CAN-2409 to a prodrug and radiation therapy in intermediate-to-high-risk prostate cancer significantly improved cancer-specific outcomes.

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Disitamab vedotin, toripalimab, and trastuzumab demonstrated superior response rates and efficacy in HER2-overexpressing metastatic gastric cancers.

Efficacy and safety outcomes in the phase 3 CONTACT-03 study were consistent regardless of patients' prior immunotherapy or tyrosine kinase inhibitor use.